Trading Profile: Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. The company operates in two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment involves in the production and sale of research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers; and provides in vitro products and avian vaccine services. This segment also offers a range of services to assist customers in the drug discovery and development process, which include assistance in the breeding and maintenance of research models; consulting and staffing services; assistance in discovery, research, development, and imaging activities; and research animal diagnostic services. The PCS segment provides preclinical services, including in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management for the discovery and development of new drugs, devices, and therapies. This segment offers services in the areas of toxicology; pathology services; bioanalysis, pharmacokinetics, and drug metabolism; discovery support; and outsourced testing of biologics and devices. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
»»» Detailed Company Profile & Chart
Charles River Laboratories International Inc current day financials: 2024-03-29 11:58:34amSymbol | Name | Purchase price | Last Price | Change | % Change |
---|---|---|---|---|---|
0.00 | |||||
Recent CRL News from Yahoo Finance & Seeking Alpha
Charles River Laboratories Publishes 2023 Corporate Citizenship Report »
WILMINGTON, Mass., March 27, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023. The 2023 report demonstrates Charles River’s priorities and commitments across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect our Planet.
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine »
Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies »
A proposed bill in Congress targets Chinese biotech businesses that play an important role in developing drugs.
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine »
WILMINGTON, Mass., March 21, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement.
Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report? »
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Older Archived News Charles River Laboratories International Inc
- Insider Trading Alert - CMS, CRL And LC Traded By Insiders.
- Charles River Laboratories International In (CRL) Stock Storming The Castle Today.
- Insider Trading Alert - CRL, BID And RTN Traded By Insiders.
- Today's Roof Leaker Stock Is Charles River Laboratories International In (CRL).
- Charles River Laboratories International In (CRL) Spotted As Roof Leaker Today.
- Insider Trading Alert - CRL, TMO And CVLT Traded By Insiders.
- Analysts' Actions -- Baidu, EMC, Exxon Mobil, NetApp and More.
- Why Charles River Labs spent $36M on a German drug testing business.
- Regen BioPharma Inc. Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application.
- Q3 2015 Charles River Laboratories International Inc Earnings Release - Before Market Open.Load More News...